PD-L1 antibody drug study for advanced lung and head/neck cancers
Treatments studied
Part of Cancer, Digestive system, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This Phase 1 trial tests a new experimental drug (PF-08046054/SGN-PDL1V) in people with advanced solid tumors that have not responded to standard treatment or can’t use it. It is designed to see how the drug works and how safe it is, with a focus on tumors that have PD-L1 seen on prior lab testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced (metastatic or unresectable) solid tumor that fits one of the study cancer types
- Your cancer must have progressed after approved treatment or you cannot take/keep taking it
- You must have had past PD-L1 testing, and your results must meet the study threshold (at least 1 on the right scoring method)
- Your cancer must have measurable disease that can be tracked on scans
- Your overall functioning must be good (ECOG 0 or 1)
- You must not have certain recent treatments or brain/spread-in-the-spine complications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
This study tests a new medicine called PF-08634404 (an antibody-drug conjugate that targets cancer cells) combined with other anti-cancer drugs in people with advanced non-small cell lung cancer. It aims to see if these combinations are safe and effective. You may be eligible if your cancer has not responded to prior treatments or if you have not received any systemic treatment for advanced disease.
This trial tests a radioactive medicine (177Lu-anti-PD-L1 sdAb) that delivers radiation to cancer cells with PD-L1 protein, which is found on some solid tumors. It is for people whose cancer has spread or come back after standard treatments.
This trial tests a new combination of two medicines (sigvotatug vedotin and pembrolizumab) for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has high levels of a protein called PD-L1. The treatment is designed to help your immune system fight the cancer more effectively, and this study aims to see how well it works.
This trial tests a new experimental drug called PF-08046054/SGN-PDL1V against a standard chemotherapy (docetaxel) for people with a type of advanced lung cancer that has PD-L1 protein on at least 1% of tumor cells and has progressed after prior treatments. The goal is to see if the new drug works better or has fewer side effects.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.